Perspective Therapeutics, Inc. (NYSE:CATX) Receives $15.14 Average Price Target from Analysts

Shares of Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nine ratings firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $15.14.

Several equities research analysts have recently weighed in on CATX shares. Royal Bank of Canada decreased their price objective on Perspective Therapeutics from $25.00 to $16.00 and set an "outperform" rating for the company in a report on Monday, November 25th. Wedbush reissued an "outperform" rating and set a $11.00 price objective (down from $20.00) on shares of Perspective Therapeutics in a research report on Thursday, November 21st. Truist Financial started coverage on shares of Perspective Therapeutics in a report on Wednesday, September 25th. They issued a "buy" rating and a $21.00 target price for the company. UBS Group initiated coverage on Perspective Therapeutics in a report on Thursday, October 24th. They set a "buy" rating and a $20.00 price target on the stock. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Perspective Therapeutics in a research note on Monday, September 9th.

Insider Buying and Selling at Perspective Therapeutics

In other Perspective Therapeutics news, CFO Jonathan Robert Hunt acquired 12,829 shares of the business's stock in a transaction on Monday, November 25th. The stock was purchased at an average price of $3.82 per share, for a total transaction of $49,006.78. Following the completion of the transaction, the chief financial officer now owns 48,800 shares of the company's stock, valued at $186,416. The trade was a 35.66 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Johan M. Spoor bought 14,500 shares of the firm's stock in a transaction on Monday, November 25th. The shares were bought at an average price of $3.78 per share, for a total transaction of $54,810.00. Following the completion of the transaction, the chief executive officer now directly owns 152,072 shares in the company, valued at approximately $574,832.16. This represents a 10.54 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 33,595 shares of company stock valued at $126,625. 3.52% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. FMR LLC increased its position in shares of Perspective Therapeutics by 3,994.9% in the third quarter. FMR LLC now owns 5,504,822 shares of the company's stock valued at $73,489,000 after buying an additional 5,370,392 shares in the last quarter. Vanguard Group Inc. increased its holdings in Perspective Therapeutics by 34.6% during the 1st quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company's stock valued at $21,158,000 after acquiring an additional 4,566,356 shares in the last quarter. Nicholson Wealth Management Group LLC acquired a new position in Perspective Therapeutics during the third quarter worth about $21,390,000. State Street Corp lifted its holdings in shares of Perspective Therapeutics by 119.6% in the third quarter. State Street Corp now owns 2,190,239 shares of the company's stock valued at $29,240,000 after purchasing an additional 1,192,812 shares in the last quarter. Finally, Hills Bank & Trust Co acquired a new stake in shares of Perspective Therapeutics in the third quarter valued at approximately $13,722,000. 54.66% of the stock is owned by hedge funds and other institutional investors.

Perspective Therapeutics Price Performance

Shares of CATX opened at $4.36 on Friday. Perspective Therapeutics has a 1-year low of $2.28 and a 1-year high of $19.05. The firm has a fifty day moving average price of $10.60 and a 200 day moving average price of $12.27.

Perspective Therapeutics (NYSE:CATX - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, hitting analysts' consensus estimates of ($0.21). The business had revenue of $0.37 million for the quarter. Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. As a group, equities analysts expect that Perspective Therapeutics will post -0.87 EPS for the current fiscal year.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.